Figure 1.
Kaplan-Meier estimates of increasing durability of responses with higher veltzumab dose levels. Time to relapse in each responder was measured from the initial treatment dose to first occurrence of a platelet count <30 × 109/L, but was censored at the time of last evaluation (ticks) if discontinued from the study prior to relapse. Results show percentages of responders continuing relapse-free after receiving either 80 (n=6) or 160 (n=3) mg doses twice 2 weeks apart [pooled for clarity], 320 mg (n=8) doses twice weekly 2 weeks apart, or 320 mg doses (n=6) once-weekly for 4 consecutive weeks (pairwise log-rank tests: 320 mg × 4 vs. 320 mg × 2, P= 0.22; 320 mg × 4 vs. 80–160 mg, P=0.17; both 320 mg doses vs. 80–160 mg, P=0.16).